- Home
- GPRK vs RCKT Comparison
GPRK vs RCKT Comparison
Compare GPRK & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- RCKT
- Stock Information
- Founded
- GPRK 2002
- RCKT 1999
- Country
- GPRK Colombia
- RCKT United States
- Employees
- GPRK N/A
- RCKT N/A
- Industry
- GPRK Oil & Gas Production
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- RCKT Health Care
- Exchange
- GPRK Nasdaq
- RCKT Nasdaq
- Market Cap
- GPRK 335.7M
- RCKT 328.6M
- IPO Year
- GPRK N/A
- RCKT N/A
- Fundamental
- Price
- GPRK $6.44
- RCKT $3.38
- Analyst Decision
- GPRK Buy
- RCKT Buy
- Analyst Count
- GPRK 1
- RCKT 13
- Target Price
- GPRK $11.00
- RCKT $12.88
- AVG Volume (30 Days)
- GPRK 1.6M
- RCKT 2.5M
- Earning Date
- GPRK 11-05-2025
- RCKT 11-06-2025
- Dividend Yield
- GPRK 9.13%
- RCKT N/A
- EPS Growth
- GPRK N/A
- RCKT N/A
- EPS
- GPRK 0.81
- RCKT N/A
- Revenue
- GPRK $560,354,000.00
- RCKT N/A
- Revenue This Year
- GPRK N/A
- RCKT N/A
- Revenue Next Year
- GPRK N/A
- RCKT $108.43
- P/E Ratio
- GPRK $7.83
- RCKT N/A
- Revenue Growth
- GPRK N/A
- RCKT N/A
- 52 Week Low
- GPRK $5.66
- RCKT $2.19
- 52 Week High
- GPRK $11.72
- RCKT $18.89
- Technical
- Relative Strength Index (RSI)
- GPRK 46.27
- RCKT 48.56
- Support Level
- GPRK $5.97
- RCKT $3.10
- Resistance Level
- GPRK $6.60
- RCKT $3.44
- Average True Range (ATR)
- GPRK 0.25
- RCKT 0.17
- MACD
- GPRK -0.00
- RCKT -0.01
- Stochastic Oscillator
- GPRK 28.63
- RCKT 36.17
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.